The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator-initiated phase II trial (NCT01703455).
Laura D. Locati
No relevant relationships to disclose
Paolo Bossi
No relevant relationships to disclose
Enrico M. Civelli
No relevant relationships to disclose
Federica Perrone
No relevant relationships to disclose
Cristiana Bergamini
No relevant relationships to disclose
Barbara Cortelazzi
No relevant relationships to disclose
Pasquale Quattrone
No relevant relationships to disclose
Martina Imbimbo
No relevant relationships to disclose
Aurora Mirabile
No relevant relationships to disclose
Roberta Granata
No relevant relationships to disclose
Carlo Resteghini
No relevant relationships to disclose
Luigi Mariani
No relevant relationships to disclose
Davide Tosarello
Employment or Leadership Position - Bayer
Camilla Cassani
No relevant relationships to disclose
Alfonso Marchiano'
No relevant relationships to disclose
Gabriella Saibene
No relevant relationships to disclose
Silvana Pilotti
No relevant relationships to disclose
Lisa F. Licitra
Research Funding - Bayer